Improving the Treatment of Brain Metastases in HER2-Positive Breast Cancers: Eternal Dream or Reality? Results of the NRG Oncology - KROG/RTOG 1119 Phase 2 Randomized Trial and Future Directions

被引：0
|
作者：
Kirova, Youlia M. [1 ,2 ]
Loap, Pierre [1 ]
机构：
[1] Inst Curie, Dept Radiat Oncol, Paris, France
[2] Univ Versailles St Quentin, Fac Med, Versailles St Quentin, France
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 118卷 / 05期
关键词：
dermal growth factor receptor 2 (HER2) - positive tumors; LAPATINIB PLUS CAPECITABINE;
D O I：
10.1016/j.ijrobp.2024.01.003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1402 / 1403
页数：2
相关论文
共 50 条
  • [41] Intracranial activity of trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients with active brain metastases: Results from the first stage of the phase II TUXEDO-1 trial
    Bartsch, R.
    Berghoff, A. S.
    Furtner, J.
    Bergen, E. S.
    Roider-Schur, S.
    Marhold, M.
    Starzer, A. M.
    Forstner, H.
    Rottenmanner, B.
    Dieckmann, K.
    Bago-Horvath, Z. A.
    Widhalm, G.
    Ilhan-Mutlu, A.
    Minichsdorfer, C.
    Fuereder, T.
    Singer, C. F.
    Weltermann, A.
    Preusser, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S486 - S486
  • [42] Combination of trastuzumab, oxaliplatin, and docetaxel as first-line treatment in HER2-positive metastatic breast cancer patients: First-step results of a phase II trial (HOT trial)
    Amoroso, D.
    Donati, S.
    Valsuani, C.
    Puccetti, C.
    Rondini, M.
    Siclari, O.
    Tartarelli, G.
    Giannessi, P.
    Falcone, A.
    Camerini, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [43] Pertuzumab retreatment in patients with HER2-positive locally advanced/metastatic breast cancer: Overall survival results of a phase III randomized trial (JBCRG-M05: PRECIOUS)
    Yamamoto, Yutaka
    Iwata, Hiroji
    Takahashi, Masato
    Yoshinami, Tetsuhiro
    Ueno, Takayuki
    Toyama, Tatsuya
    Yamanaka, Takashi
    Takano, Toshimi
    Kashiwaba, Masahiro
    Tsugawa, Koichiro
    Hasegawa, Yoshie
    Tamura, Kenji
    Tada, Hiroshi
    Hara, Fumikata
    Taira, Naruto
    Saji, Shigehira
    Morita, Satoshi
    Toi, Masakazu
    Ohno, Shinji
    Masuda, Norikazu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] Neoadjuvant bevacizumab (B) and trastuzumab (T) in combination with weekly paclitaxel (P) as neoadjuvant treatment in HER2-positive breast cancer: Results from a phase II trial (AVANTHER)
    Fernandez Abad, Maria
    Calvo, Isabel
    Martinez, Noelia
    Herrero, Mercedes
    Quijano, Yolanda
    Duran, Hipolito
    Garcia Aranda, Mariola
    Suarez, Ana
    Lopez-Rios, Fernando
    Perez, Diego
    Perea, Sofia
    Hidalgo, Manuel
    Garca-Estevez, Laura
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [45] Phase I study of lapatinib (L) and temozolomide (T) combination for the treatment of progressive brain metastases (BM) in HER2-positive metastatic breast cancer patients (Pts) (LAPTEM, LAP 111172).
    De Azambuja, E.
    Lemort, M.
    Rossari, J. R.
    Moulin, C.
    Buttice, A.
    D'hondt, V.
    Lebrun, F.
    Lalami, Y.
    Cardoso, F.
    Sotiriou, C.
    Gil, T.
    Devriendt, D.
    Marinus, W. J.
    Paesmans, M.
    Piccart, M.
    Awada, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [46] A phase III trial evaluating pCR in patients with HR+, HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) plus /- estrogen deprivation: NRG Oncology/NSABP B-52
    Rimawi, M. F.
    Cecchini, R. S.
    Rastogi, P.
    Geyer, C. E., Jr.
    Fehrenbacher, L.
    Stella, P. J.
    Dayao, Z.
    Rabinovitch, R.
    Dyar, S. H.
    Flynn, P. J.
    Baez-Diaz, L.
    Paik, S.
    Swain, S. M.
    Mamounas, E. P.
    Osborne, C. K.
    Wolmark, N.
    CANCER RESEARCH, 2017, 77
  • [47] Triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer (MBC): latest results of an international phase II trial
    Chan, A.
    Ganju, V.
    Becquart, D.
    Conte, P. F.
    Petruzelka, L.
    Perrot, O.
    Villanova, G.
    Tubiana-Mathieu, N.
    EJC SUPPLEMENTS, 2007, 5 (04): : 221 - 222
  • [48] Capecitabine (X) plus trastuzumab (H) as first-line treatment in patients (pts) with HER2-positive metastatic breast cancer (MBC): phase II trial results.
    Xu, L.
    Song, S.
    Zhu, J.
    Luo, R.
    Li, L.
    Jiao, S.
    Pan, H.
    Tao, M.
    Su, Y.
    Liu, D.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S102 - S102
  • [49] LUX-Breast 3: Randomized Phase II trial of afatinib (BIBW 2992) alone or with vinorelbine versus investigator's choice of treatment in patients (pts) with HER2-positive breast cancer (BC) with progressive brain metastases after trastuzumab and/or lapatinib-based therapy*
    Joensuu, H.
    Ould-Kaci, M.
    CANCER RESEARCH, 2012, 72
  • [50] Safety Analyses of NRG BR004: A Randomized, Double-blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-line HER2-Positive Metastatic Breast Cancer (MBC)
    Geyer, Charles E., Jr.
    Tang, Gong
    Rastogi, Priya
    Valero, Vicente
    Chia, Stephen K.
    Cobain, Erin F.
    Obeid, Elias
    Page, David B.
    Poklepovic, Andrew S.
    Irvin, William J., Jr.
    Brufsky, Adam M.
    Wapnir, Irene L.
    Suga, Jennifer M.
    Mamounas, Eleftherios
    Wolmark, Norman
    CANCER RESEARCH, 2023, 83 (05)
12345